Cardlytics Past Earnings Performance

We're still processing the latest earnings report of this company

Past criteria checks 0/6

Key information

-41.8%

Earnings growth rate

-36.4%

EPS growth rate

Media Industry Growth	13.2%
Revenue growth rate	12.2%
Return on equity	-73.0%
Net Margin	-50.2%
Last Earnings Update	30 Jun 2024

Recent past performance updates

Recent updates

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Nov 05

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Oct 15

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Sep 17

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Aug 09

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Jul 02

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

May 31

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Apr 17

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?

Mar 03

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Jan 10

Is Cardlytics (NASDAQ:CDLX) Using Debt In A Risky Way?

Oct 12

Cardlytics: 6 Bear Cases To Consider

Oct 10

Revenue & Expenses Breakdown

How Cardlytics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:CDLX Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	305	-153	117	51
31 Mar 24	312	-173	118	53
31 Dec 23	309	-135	116	51
30 Sep 23	303	-412	126	53
30 Jun 23	296	-382	129	53
31 Mar 23	295	-485	141	52
31 Dec 22	299	-465	152	53
30 Sep 22	306	-99	150	50
30 Jun 22	298	-150	154	49
31 Mar 22	282	-71	145	44
31 Dec 21	267	-129	132	38
30 Sep 21	244	-124	120	31
30 Jun 21	225	-94	107	25
31 Mar 21	195	-67	95	20
31 Dec 20	187	-55	91	17
30 Sep 20	189	-45	88	15
30 Jun 20	199	-38	88	14
31 Mar 20	220	-24	85	13
31 Dec 19	210	-17	81	12
30 Sep 19	189	-32	84	13
30 Jun 19	167	-33	78	14
31 Mar 19	154	-39	78	16
31 Dec 18	151	-53	76	16
30 Sep 18	142	-46	65	15
30 Jun 18	139	-41	61	14
31 Mar 18	136	-33	55	13
31 Dec 17	130	-25	52	12
30 Sep 17	128	-28	52	12
30 Jun 17	127	-51	50	12
31 Mar 17	120	-77	51	12
31 Dec 16	113	-77	52	13
31 Dec 15	78	-42	51	12

Cardlytics Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Cardlytics, Inc. Reports Unaudited Consolidated Impairment of Goodwill and Intangible Assets for the Three Months Ended September 30, 2024

Cardlytics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Cardlytics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cardlytics, Inc. to Report Q1, 2024 Results on May 08, 2024

Cardlytics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Recent updates

Cardlytics, Inc. Reports Unaudited Consolidated Impairment of Goodwill and Intangible Assets for the Three Months Ended September 30, 2024

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Cardlytics, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2024

Cardlytics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Cardlytics, Inc. to Report Q1, 2024 Results on May 08, 2024

The Power Of Cardlytics' Data Partnerships Including Bank of America

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

CEO & Director notifies of intention to sell stock

Now 35% undervalued

Consensus estimates of losses per share improve by 18%

Cardlytics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Cardlytics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 46% to US$17.00

New major risk - Share price stability

No longer forecast to breakeven

Cardlytics, Inc. Provides Earnings Guidance for the First Quarter of 2024

CEO & Director notifies of intention to sell stock

Cardlytics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Cardlytics: Good Prospects But Macro Uncertain

High number of new directors

COO & GM of Bridg exercised options and sold US$443k worth of stock

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

CEO & Director notifies of intention to sell stock

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Kigo, LLC acquired HSP EPI Acquisition, LLC from Cardlytics, Inc. (NasdaqGM:CDLX).

CEO & Director exercised options and sold US$332k worth of stock

Consensus EPS estimates upgraded to US$1.32 loss, revenue downgraded

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Announces Resignation of Tony Weisman as Member of the Board and as Member of the Nominating and Corporate Governance Committee

Cardlytics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Cardlytics, Inc. Appoints Alex Mishurov as Independent Director

CEO & Director recently sold US$2.9m worth of stock

Cardlytics, Inc. Announces Board Member Changes

Insider recently sold US$172k worth of stock

Consensus EPS estimates fall by 29%, revenue upgraded

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Insufficient new directors

Cardlytics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Cardlytics Appoints Alexis Desieno as New Chief Financial Officer

Cardlytics, Inc. Announces Board Changes

Cardlytics, Inc. Announces Board Changes

CEO & Director notifies of intention to sell stock

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$1.87 loss, revenue downgraded

Price target increased by 9.8% to US$6.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Price target increased by 8.9% to US$6.10

Full year 2022 earnings: EPS misses analyst expectations

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?